Part 1: Robotic Exoskeletons | April 25th, 2025
This session explored the clinical translation of robotic exoskeletons, with a focus on collaboration between engineers, clinicians, and industry leaders. Presenters from Wandercraft discussed ongoing clinical trials, the pathway to market, and key considerations for payer access.
Presenters:
Josh Breighner, PT, DPT, is the Reimbursement, Access, and Policy Manager for Wandercraft. He focuses on demonstrating the value of and improving patient access to innovative robotic exoskeleton technology. As a Board-Certified Clinical Specialist in Neurologic Physical Therapy, he believes strongly in the role of advanced technology in enhancing neurological rehabilitation. His transition to a “non-clinical” role has enabled him to apply his clinical and research experiences to the rapidly evolving exoskeleton industry, ensuring that this technology reaches those who need it most, while still keeping close ties to clinical practice. Additionally, Josh is the owner of Walk in New York by Wandercraft, a physical therapy practice in New York, NY. This practice utilizes Wandercraft’s innovative rehabilitation exoskeleton, Atalante X, as well as other advanced technologies, to improve patient outcomes.
Laure Bouché : As clinical engineer at Wandercraft, her role is to contribute to the design and execution of clinical studies essential for the deployment of Wandercraft’s exoskeletons. She initially worked on Atalante—Wandercraft’s rehabilitation exoskeleton, already in use in Europe and the U.S.—where efforts are focused on expanding its indications and demonstrating clinical benefits through the first randomized controlled trials. Now, she is also involved in the development of the Personal Exoskeleton, aiming to secure FDA clearance for individuals with spinal cord injuries at or above T6, as an initial indication. Before joining Wandercraft, she completed an engineering degree in France, with a specialization in biomedical sciences.
